

Sanofi and VNVC to establish a vaccine manufacturing facility in Vietnam with a \$77M initial investment

27 May 2025 | News

The facility is projected to produce 100 million doses annually, with operations expected to begin by the end of 2027.



Sanofi and Vietnam Vaccine JSC, or VNVC, launched a project on 27 May to establish vaccine manufacturing facility in Vietnam. The facility is expected to producing vaccines for domestic and international markets.

The launch was witnessed by French President Emmanuel Macron during his visit to the Southeast Asian country. French president and state president Luong Cuong exchanged documents on vaccine production technology transfer between Sanofi and VNVC. As of October 2024, the two countries have upgraded their relationship to Comprehensive Strategic Partnership.

The plant, situated in the southern province of Long An, spans 2.6 hectares (6.4 acres) and has received an initial investment of 2 trillion dong (\$77.19 million).

The facility is projected to produce 100 million doses annually, with operations expected to begin by the end of 2027. Sanofi and VNVC will gradually implement technology transfer to produce some important Sanofi vaccines in Vietnam. In addition, Sanofi also accompanies VNVC in training human resources and quality management in vaccine research and production.

Furthermore, this event was an important step toward developing bilateral health relations, not only through trade and human resource training, but also through scientific research collaboration, technology transfer, and high-tech production. The Vietnamese health sector also hopes to expand international cooperation in high-level science and technology, improve its ability to respond to future epidemic challenges, and lay the foundation for outstanding developments in biomedicine.